Chromocell therapeutics announces pricing of upsized $6.6 initial public offering

Freehold, n.j., feb. 16, 2024 (globe newswire) -- chromocell therapeutics corporation (nyse american: chro) (“chromocell” or the “company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share. the offering raised aggregate gross proceeds of approximately $6.6 million, prior to deducting underwriting discounts and other offering expenses.
CHRO Ratings Summary
CHRO Quant Ranking